EpiVacCorona (Russian: ЭпиВакКорона, tr. EpiVacCorona) is a peptide-based vaccine against COVID-19 developed by the Russian VECTOR Center of Virology... 39 KB (3,883 words) - 03:25, 12 February 2024 |
Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. United States National... 318 KB (19,351 words) - 20:33, 14 March 2024 |
CoronaVac, also known as the Sinovac COVID-19 vaccine, is a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech... 120 KB (11,030 words) - 21:48, 14 April 2024 |
SARS-CoV-2 Beta variant (section EpiVacCorona) neutralization. The CoviVac vaccine Information has not been delivered to the South African government yet. The EpiVacCorona vaccine Information has not... 72 KB (6,070 words) - 06:39, 3 February 2024 |
COVID-19 vaccine (redirect from Corona vaccine) Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. 22 September 2020.... 192 KB (21,930 words) - 19:29, 15 April 2024 |
iNCOVACC sixteen subunit vaccines: Abdala, Corbevax, COVAX-19, EpiVacCorona, IndoVac, MVC-COV1901, Noora, Novavax, Razi Cov Pars, Sanofi–GSK, Sinopharm... 98 KB (20,593 words) - 02:58, 8 March 2024 |
Rotavirus# Rubella# SARS-CoV-2 Corbevax† Bharat Biotech† CanSino† CoronaVac† EpiVacCorona† Janssen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sanofi–GSK†... 65 KB (6,721 words) - 12:17, 22 March 2024 |
Rotavirus# Rubella# SARS-CoV-2 Corbevax† Bharat Biotech† CanSino† CoronaVac† EpiVacCorona† Janssen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sanofi–GSK†... 27 KB (3,005 words) - 15:52, 13 March 2024 |